 Connection
Nicholas Cost to Testicular Neoplasms
This is a "connection" page, showing publications Nicholas Cost has written about Testicular Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
9.738 |
|
|
|
-
Wiesen B, Atwell M, Leavitt C, Clark N, Kessler E, Lam E, Flaig T, Kukreja J, Kim S, Maroni P, Cost NG. Use of Peripheral Intravenous Access in Patients Undergoing Chemotherapy for Testicular Cancer. JCO Oncol Pract. 2024 Mar; 20(3):361-369.
Score: 0.817
-
Saltzman AF, Hensley P, Ross J, Woo L, Billmire D, Rescorla F, Puri D, Patel S, Pierorazio P, Bagrodia A, Cary C, Cost NG. Critical elements of pediatric testicular germ cell tumors surgery. Semin Pediatr Surg. 2023 Oct; 32(5):151343.
Score: 0.812
-
Meier KM, Linton A, Baldes C, Demedis J, Cost NG. Peripubertal Presentation of Metastatic Testicular Mixed, Nonseminomatous Germ Cell Tumor. Urology. 2024 02; 184:e239-e242.
Score: 0.811
-
Caldwell BT, Saltzman AF, Maccini MA, Cost NG. Appropriateness for testis-sparing surgery based on the testicular tumor size in a pediatric and adolescent population. J Pediatr Urol. 2019 Feb; 15(1):70.e1-70.e6.
Score: 0.571
-
Brodie KE, Saltzman AF, Cost NG. Adolescent testicular microlithiasis: A case-based, multinational survey of clinical management practices. J Pediatr Urol. 2018 04; 14(2):151.e1-151.e8.
Score: 0.543
-
Stokes W, Amini A, Maroni PD, Kessler ER, Stokes C, Cost CR, Greffe BS, Garrington TP, Liu AK, Cost NG. Patterns of care and survival outcomes for adolescent and young adult patients with testicular seminoma in the United States: A National Cancer Database analysis. J Pediatr Urol. 2017 Aug; 13(4):386.e1-386.e7.
Score: 0.506
-
Rove KO, Maroni PD, Cost CR, Fairclough DL, Giannarini G, Harris AK, Schultz KA, Cost NG. Pathologic Risk Factors for Metastatic Disease in Postpubertal Patients With Clinical Stage I Testicular Stromal Tumors. Urology. 2016 11; 97:138-144.
Score: 0.491
-
Amini A, Waxweiler TV, Maroni PD, Kessler ER, Cost CR, Greffe BS, Garrington TP, Liu AK, Cost NG. Survival outcomes of adolescent and adult patients with non-seminomatous testicular germ-cell tumors: A population-based study. J Pediatr Urol. 2016 Dec; 12(6):405.e1-405.e9.
Score: 0.490
-
Cost NG, Caldwell BT, Adibi M, Raj GV, Sagalowsky AI, Margulis V. Do Referral Patterns in Adolescents and Young Adults with Testicular Cancer Impact Oncologic Outcomes? J Adolesc Young Adult Oncol. 2016 09; 5(3):248-53.
Score: 0.474
-
Rove KO, Maroni PD, Cost CR, Fairclough DL, Giannarini G, Harris AK, Schultz KA, Cost NG. Pathologic Risk Factors in Pediatric and Adolescent Patients With Clinical Stage I Testicular Stromal Tumors. J Pediatr Hematol Oncol. 2015 Nov; 37(8):e441-6.
Score: 0.465
-
Grantham EC, Caldwell BT, Cost NG. Current urologic care for testicular germ cell tumors in pediatric and adolescent patients. Urol Oncol. 2016 Feb; 34(2):65-75.
Score: 0.455
-
Cost NG, Lubahn JD, Adibi M, Romman A, Wickiser JE, Raj GV, Sagalowsky AI, Margulis V. Risk stratification of pubertal children and postpubertal adolescents with clinical stage I testicular nonseminomatous germ cell tumors. J Urol. 2014 May; 191(5 Suppl):1485-90.
Score: 0.416
-
Cost NG, Maroni P, Flaig TW. Metastatic relapse after initial clinical stage I testicular Leydig cell tumor. Oncology (Williston Park). 2014 Mar; 28(3):211, 214.
Score: 0.414
-
Cost NG, Lubahn JD, Adibi M, Romman A, Wickiser JE, Raj GV, Sagalowsky AI, Margulis V. A comparison of pediatric, adolescent, and adult testicular germ cell malignancy. Pediatr Blood Cancer. 2014 Mar; 61(3):446-51.
Score: 0.401
-
Cost NG. Testicular germ cell tumors. Current concepts and management strategies. Minerva Urol Nefrol. 2013 Jun; 65(2):133-55.
Score: 0.393
-
Cost NG. Editorial comment. Urology. 2013 Jul; 82(1):223; discussion 223-4.
Score: 0.384
-
Cost NG, Adibi M, Lubahn JD, Romman A, Raj GV, Sagalowsky AI, Margulis V. Effect of testicular germ cell tumor therapy on renal function. Urology. 2012 Sep; 80(3):641-8.
Score: 0.371
-
Jarvis H, Cost NG, Saltzman AF. Testicular tumors in the pediatric patient. Semin Pediatr Surg. 2021 Aug; 30(4):151079.
Score: 0.172
-
Golmard L, Vasta LM, Duflos V, Corsini C, Dubois d'Enghien C, McMaster ML, Harney LA, Carr AG, Ling A, Dijoud F, Gauthier A, Miettinen M, Cost NG, Gauthier-Villars M, Orbach D, Irtan S, Haouy S, Schultz KA, Stoppa-Lyonnet D, Coupier I, Stewart DR, Sirvent N. Testicular Sertoli cell tumour and potentially testicular Leydig cell tumour are features of DICER1 syndrome. J Med Genet. 2022 04; 59(4):346-350.
Score: 0.169
-
Gilligan T, Lin DW, Aggarwal R, Chism D, Cost N, Derweesh IH, Emamekhoo H, Feldman DR, Geynisman DM, Hancock SL, LaGrange C, Levine EG, Longo T, Lowrance W, McGregor B, Monk P, Picus J, Pierorazio P, Rais-Bahrami S, Saylor P, Sircar K, Smith DC, Tzou K, Vaena D, Vaughn D, Yamoah K, Yamzon J, Johnson-Chilla A, Keller J, Pluchino LA. Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 12; 17(12):1529-1554.
Score: 0.154
-
Higgins M, Smith DE, Gao D, Wilcox D, Cost NG, Saltzman AF. The impact of age at orchiopexy on testicular cancer outcomes. World J Urol. 2020 Oct; 38(10):2531-2536.
Score: 0.154
-
Luckie TM, Danzig M, Zhou S, Wu H, Cost NG, Karaviti L, Venkatramani R. A Multicenter Retrospective Review of Pediatric Leydig Cell Tumor of the Testis. J Pediatr Hematol Oncol. 2019 01; 41(1):74-76.
Score: 0.145
-
Caldwell BT, Wilcox DT, Cost NG. Current Management for Pediatric Urologic Oncology. Adv Pediatr. 2017 08; 64(1):191-223.
Score: 0.131
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|